Laurantis Pharma Oy

Laurantis is a clinical-stage specialty pharmaceutical development company formed through the merger of two independent companies, BioCis Pharma Oy and Oy Lx Therapies Ltd in late 2010. Laurantis has a broad portfolio of first-in-class products based on two proprietary technologies. The Company’s lead products target the treatment of a variety of inflammatory diseases and conditions including atopic dermatitis, dry eye syndrome, interstitial cystitis, and lymphatic disorders, as well as the treatment of bladder cancer.